FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934
For the months of December 2002 though February 2003
Biacore International AB (publ)
C/o Biacore International SA
Puits-Godet 12
CH-2000 Neuchatel
Switzerland
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.
Form 20-F X
Form 40-F
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
of 1934.
Yes
No X
If "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b):
YEAR-END REPORT 2002
* Biacore's sales in 2002 increased by 13% to SEK 614.2 million (543.7).
Excluding the impact of exchange rates, sales rose by 14%. Sales in the fourth
quarter amounted to SEK 175.9 million (175.0).
* Biacore's earnings per share in 2002 increased by 63% to SEK 8.20 (5.04) due
to careful cost controls and the one-off benefits from the successful defence
of the Company's IP position in the U.S. This very positive earnings
performance was achieved even after investing heavily in the new SPR array
chip technology, as well as making provisions to reflect the lower value of
some of the Company's earlier investments in biotech companies. Earnings per
share in the fourth quarter were SEK 4.15 (1.68), an increase by 147%.
* Reflecting Biacore's continued strong cash flow, the Board will recommend to
the Annual General Meeting that the Company begins to pay dividends to its
shareholders. For the financial year 2002 the Board will recommend a dividend
payment of SEK 3.00 per share.
* Taking into consideration the general market conditions and currency
developments, Biacore's sales for the full-year 2003 are expected to increase
by approximately 10%. Earnings per share are forecast to increase by
approximately 70% in 2003. Earnings per share will be positively affected by a
considerable reduction of the tax rate compared with full-year 2002 and the
capitalization of R&D expenses of approximately SEK 40 million in accordance
with Swedish accounting rules. As always, sales and earnings are expected to
vary substantially between the quarters.
January - December October - December
2002 2001 Change 2002 2001 Change
Sales, SEK million 614.2 543.7 +13% 175.9 175.0 1%
Operating income,
SEK million 140.6 64.1 119% 48.5 25.7 89%
Operating margin, % 23 12 28 15
Income after financial
items, SEK million 120.2 77.9 54% 49.6 27.7 79%
Diluted earnings
per share, SEK 8.20 5.04 63% 4.15 1.68 147%
Operational Review January-December 2002
Amounts stated in this report pertain to the Biacore Group, unless indicated
otherwise. Figures in parentheses refer to the corresponding period in 2001.
Biacore's standing as one of the world's most successful bio-analytical
instrumentation companies was enhanced in 2002. The strength of its SPR
technology-based product offering, its global sales capability and its strong
IP position enabled Biacore to achieve a significant improvement in both sales
and earnings despite the testing global economic conditions experienced by most
bio-analytical companies.
For the full-year 2002, the Company's sales increased by 13% to SEK 614.2
million. Excluding currency effects, sales increased by 14%. The growth in
sales achieved in 2002 reflects the unique benefits of the Company's SPR
technology and the strength of its customer base, particularly key academic
centers around the world. After a very strong third quarter 2002, sales in the
fourth quarter were level with the previous year at SEK 175.9 million (175.0).
These variations are normal in Biacore's business.
Biacore(r)3000 continues to be the Company's best-selling product. This
flexible system is Biacore's most important product offering to academic
customers in its core basic life science research market. Biacore(r)3000 is
used to solve a wide range of biological research problems, especially in the
field of functional proteomics.
The fourth quarter of 2002 saw further sales of the Company's new
Biacore(r)S51. This new system has been designed for lead optimization and
certain specific ADME applications, two of the key problem areas faced by the
drug discovery industry today. The final quarter of 2002 also saw further
sales of Biacore(r)C, which is used for manufacturing quality control
applications.
Sales were divided geographically as follows:
January-December October - December
SEK million 2002 2001 Change 2002 2001 Change
Americas 270.5 249.3 9% 63.8 63.4 1%
Europe 173.9 151.0 15% 62.7 63.5 -1%
Asia-Pacific 169.8 143.4 18% 49.4 48.1 3%
Sales in the Americas were affected by a slowdown in orders from the
pharmaceutical and biotechnology sector. Despite this, sales increased by 9%
to SEK 270.5 million in 2002 (249.3). Sales in Europe in 2002 were more
buoyant, increasing by 15% to SEK 173.9 million (151.0). Sales also continued
to grow well in Asia-Pacific with revenues up 18% to SEK 169.8 million
(143.4).
The 83.6% gross margin achieved for the whole of 2002 was consistent with
prior periods.
As forecast, the Company has continued to keep a tight control of its
operating costs. Total costs for marketing, administration and research and
development decreased by 2% in 2002 to SEK 372.5 million (380.1). In the
fourth quarter, marketing and sales costs decreased by 5% to SEK 53.4 million
(56.3), while administration costs fell by 52% to SEK 13.6 million (28.3).
This decline is largely due to the 2001 figure including a charge of SEK 13
million for pension entitlements to the former Chief Executive Officer.
R&D spending in the fourth quarter declined marginally to SEK 26.3 million
(27.0). This follows significant increases in both 2000 and 2001. The
reduction in spending reflected the completion of the development of
Biacore(r)S51 and Biacore(r)C, which were launched in the second half of 2001,
as well as the capitalization of SEK 5.0 million (0.0) of R&D expenses due to
a change in Swedish accounting standards on R&D expenses that came into effect
at the beginning of 2002. During 2002, a total of SEK 35.0 million was spent
to commercialize Biacore's unique SPR array chip technology. In 2001, Biacore
invested SEK 29.9 million in this project.
The increase in sales, allied to the Company's tight control of costs and the
SEK 19.6 million payment in damages from Thermo related to the patent dispute
in the U.S., resulted in operating income increasing by 119% to SEK 140.6
million in 2002. The operating margin for 2002 was 22.9%. Currency differences
during 2002 amounted to SEK -16.6 million (4.5) in 'Other income and expenses'
and SEK 0.0 million (0.2) in 'Financial items'. These changes were due to the
depreciation of the U.S. dollar and the Japanese yen against the Swedish Krona.
Due to the continuing adverse conditions within the early stage biotech
community, Biacore decided to make a total provision of SEK 28.7 million in
2002 (0.0) against its equity portfolio in this sector.
The effective tax rate for 2002 was 33% (35) of income after financial items.
The tax rate has been affected by losses on equity investments only being
deductible against gains on such investments. Biacore has no realized or
unrealized gain on any such investment against which it could offset any loss.
This adverse impact was partly offset by a change in the geographical mix in
income, one factor being the establishment of the group headquarters in
Switzerland.
Net income for 2002 was SEK 80.8 million (50.3), giving a 63% increase in
diluted earnings per share to SEK 8.20 (5.04). Earnings per share in the
fourth quarter was SEK 4.15 (1.68), an increase of 147%.
The strong earnings before depreciation, amortization and write-downs of
equity investments was the main factor behind the net cash from operating
activities of SEK 163.7 million in 2002.
Investing Activities
During 2002, capital expenditures totaled SEK 31.7 million (40.0).
Personnel
At the end of December 2002, Biacore had 325 (288) permanent employees.
Magnus Lundberg, president of Pharmacia Diagnostics, was elected new director
of the Board at the Annual General Meeting in May, 2002.
In January 2002, Ulf Jonsson, President of Biacore, also became Chief
Executive Officer of Biacore. The Company's former CEO and Executive Chairman,
Lars-Goran Andren, continues as non-executive Chairman of the Board.
In May 2002, Biacore introduced a new incentive stock option program involving
a maximum of 80,000 new Biacore shares. The program is mainly directed to
employees in the United States and newly employed personnel.
Business Review
Biacore has clearly demonstrated that it is one of the world's most successful
bio-analytical instrumentation companies with sales increasing from SEK 340
million in 1999 to SEK 614 million in 2002.
This success is due to Biacore's world leading position in the
commercialization of surface plasmon resonance (SPR) technology, which is used
for the real-time detection and monitoring of biomolecular binding
interactions. Identifying and characterizing the sometimes small changes in
the way biomolecules interact can greatly increase understanding of the causes
of disease as well as the differences in the effectiveness of different drug
therapies.
Biacore's well-balanced customer base, which spans the world's leading life
science research institutes, leading companies in the pharmaceutical and
biotechnology industries and major food manufacturers, has also been a major
factor in the company's success.
Biacore has concentrated on capitalizing on the high value opportunities for
its SPR technology to these customers. However, over time, the Company expects
important commercial applications of its SPR technology to be generated in a
number of other industries.
Growing Applications for Academic Customers
In the last two years, Biacore's marketing activities have focused on the
ability of its SPR technology based systems to help solve many of the
important problems faced by academic scientists working on a better
understanding of the molecular causes of disease.
Key areas where Biacore has focused its marketing include Cancer, Neuroscience
and more recently Infectious Diseases.
Another key area is Proteomics, where the Company is a global leader. In the
field of functional proteomics there are two areas where Biacore's SPR systems
are clearly recognized as being of great value, ligand fishing and protein
interactions. These areas are both crucial to developing a clear understanding
of disease and for identifying drug-like structures that may prove the basis
of potential drug candidates.
Bruker Daltonics Collaboration - Focus on Functional Proteomics
In October 2001, Biacore signed an important collaboration with the Nasdaq
listed company Bruker Daltonics designed to combine the power of the two
companies' core technologies, SPR and mass spectrometry, respectively.
Together, the companies aim to commercialize the combined technique of SPR-MS
in order to create an exciting comprehensive platform for functional
proteomics studies. This new combined technical solution will help researchers
to:
* Generate functional information on proteins, receptors and ligands of
interest,
* Isolate and purify these molecules, and
* Characterize and identify these proteins or other molecules of interest.
A growing number of customers has begun to explore this powerful technology
combination across an array of applications in areas as diverse as cancer
research, plant biology and product quality assurance; and with the continuing
collaboration the increased understanding of the methodology has led to a
number of new applications.
In response to the needs for more automated and larger capacity recovery as
well as the ability to directly deposit targets to a matrix-assisted laser
desorption ionization (MALDI), Biacore has been developing a new module for
Biacore(r)3000 which will further enhance and integrate the SPR-MS approach
with launch later in 2003.
Biacore is confident that the SPR-MS technology combination will provide
researchers with a radical new approach to functional proteomics studies and
will give both companies a strong competitive position in the rapidly growing
proteomics market.
Developing High Quality Drug Candidates
In parallel to generating clearer insights into the causes of disease,
Biacore's SPR technology based systems are being used by pharmaceutical and
biotechnology companies to discover and develop better drugs for the treatment
of a wide range of diseases.
Frost & Sullivan Awards for Drug Discovery Technology
In November, Biacore received the Frost & Sullivan Awards for Drug Discovery
Enabling Technology of the Year 2002 and Product Innovation in the field of
protein arrays. Biacore received the award based on its successful launch of
new products and technologies within its industry as well as innovation
through the development of a broad line of emerging systems platforms. Biacore
gained the awards based on an evaluation of the world drug discovery and
protein array markets by the management consultants Frost & Sullivan. In its
recent report analyzing the 'World Protein Array Market,' Frost & Sullivan
showed that Biacore is well positioned to benefit from the explosive growth of
the global protein array market, which is expected to expand by more than 50%
per annum over the next five years to be worth USD 665 million in 2007.
Biacore's industry leading position was determined by an analysis of new
product launches and new products in development by the companies in this
field. These were then compared based on the degree of innovation and customer
satisfaction. The companies included in the industry survey were then ranked
by the number of new product launches and new products in development.
Biacore(r)S51- Gaining Ground with The Industry Leaders
In late 2001, Biacore introduced its first system specifically designed for
the pharmaceutical and biotechnology industry. This new system, Biacore(r)S51,
addresses critical bottlenecks in the drug discovery process downstream of
high throughput screening (HTS). Biacore(r)S51 is able to achieve this by
providing more relevant biological information on compound activity, in a
single assay, than any other technology available today.
Sales of this new system have been made to leading pharmaceutical and
biotechnology companies around the globe. Given the progress that has been
made with Biacore(r)S51 since its launch, we are confident that it will be a
major contributor to the Company's future sales growth. This confidence is
also based on two other key developments:
* New customer-generated data highlighting the benefits of using Biacore(r)S51
is expected to become increasingly available during the course of 2003, and
* New applications for the Biacore(r)S51, based on the work of leading
university research particularly in the area of structure activity
relationships.
Procel(tm) - A Complementary Cell-Based System
In November 2002, Biacore introduced its new cell-based assay system,
Procel(tm). This product has resulted from Biacore acquiring a license to the
proprietary fluorescent cell-based assay technology developed by the U.S.
company Axiom Biotechnologies Inc.
Procel(tm), which will have its full commercial launch in March 2003 at the
Screentech Conference in San Diego, is designed to complement Biacore(r)S51
and provide a highly competitive offering in the field of lead optimization.
By using Procel(tm), researchers will have access to an easy-to-use cell-based
fluorescent analytical system which has been designed to characterize
compounds that interact with both G protein coupled receptors (GPCRs) and ion
channels. These are two of the main classes of drug targets under evaluation
today.
Procel(tm) is able to carry out a number of important applications, which are
crucial in the lead optimization process.
Biacore is confident that the combination of Procel(tm) and Biacore(r)S51
will provide researchers with access to detailed information on the biological
activity of potential drug candidates in a competitive timeframe and to a
depth and quality superior to existing analytical instrumentation. The
complementary nature of these two products is also expected to lead to
synergies in the Company's sales and marketing efforts.
SPR Array Chip Technology - Higher Information Content
In the late 1990s, Biacore's scientists made a number of important
technological breakthroughs in SPR detection and micro-fluidics that have
paved the way for the development of a new SPR array chip system. This system
is expected to be able to deliver an exponential improvement in the speed with
which information on protein interactions can be generated and is expected to
be introduced in 2004. Delivering the same high sensitivity and data quality
that the Company's customers currently enjoy and require, this new platform
will enable Biacore's SPR technology to be used in a wide range of
applications. With appeal to scientists in major scientific institutes and in
the pharmaceutical and biotechnology industry alike, it will be used for both
basic life science research and for drug discovery and development
applications.
To commercialize its SPR array chip technology Biacore has entered into two
collaborations to develop specific applications and gain access to reagent
expertise. These collaborations and relationships are enabling Biacore to
develop the critical elements in the specification of the system to meet the
demands of the end-users.
The first collaboration started in June 2000 with Millennium Pharmaceuticals
Inc. to examine potential applications of SPR array chip technology and has
progressed as anticipated. By collaborating with Millennium, Biacore expects
to be able to develop new systems that are tailored to the needs of major
customers in the pharmaceutical/biotechnology industry.
Valuable input from Millennium's scientists on applications and industry needs
has enabled R&D efforts to focus on the key array technology format that will
meet the requirements of Biacore's major target customer groups for higher
throughput SPR instrumentation. The agreed format will build on the
fundamental advantages of Biacore's proprietary SPR and micro-fluidics
technology, emphasizing sensitivity, data quality and high information
content, combined with an increase in throughput that meets industry needs.
The SPR array chip system is designed for applications in the interaction
proteomics and post-HTS small molecule characterization areas, where its
sensitivity, increased throughput and high information content will complement
Biacore's existing systems. Over time, the Company expects the SPR array chip
system to have applications across the spectrum of drug discovery and
development activities and be a valuable tool in many proteomics applications.
In order to address higher throughput proteomics applications, it is crucial
to have access to the right reagents. To achieve this, Biacore signed a
further complementary collaboration with the U.S. company BD Biosciences
Pharmingen in July 2002. This collaboration provides access to targeted panels
of antibodies and reagents for array applications.
SPR Technology in the Food Industry
In November 2002, the positive results from Biacore's involvement in the
important EC food safety improvement project, FoodSENSE, were presented at
European Research 2002. This project demonstrated the applicability of
Biacore's SPR biosensor based technology for the high throughput analysis of
potentially harmful contaminants and chemical residues in food. Few techniques
have the necessary throughput, reliability, reproducibility or sensitivity to
satisfy the challenging requirements of the food industry. However, final
results from FoodSENSE have shown that a substantially higher daily throughput
of tests (up to 650 samples/day) can be performed using Biacore's SPR
technology, with the capacity to rapidly detect a much wider range of residues
compared with existing test methods.
Future Growth Prospects Remain Positive
Biacore's progress in 2002 has put the Company in a strong position to deliver
an exciting rate of growth going forward. Factors which are expected to play a
key role in driving future returns to shareholders include:
* The continued growth which is expected from the Company's core life science
research customers as a result of Biacore's marketing efforts leading to a
greater recognition of the value of SPR technology in the field of functional
proteomics,
* The anticipated success of the collaboration with Bruker Daltonics which
will allow the commercialization of a system which delivers the powerful
combination of SPR-MS for proteomics applications,
* The continued growth of the two systems introduced in 2001 to meet the
specific needs of customers in the pharmaceutical and biotechnology industry,
Biacore(r)S51 for 'hit' to lead selection and Biacore(r)C for QC (quality
control) applications,
* The forthcoming full commercial launch of Procel(tm), the new cell based
assay system that will complement Biacore(r)S51 in the field of lead selection,
and
* The undoubted potential for the new products that are being developed based
on Biacore's novel SPR array chip technology.
Accounting Principles
As of 2002, a number of new standards from the Swedish Financial Accounting
Standards Council have become effective. The adoption of these new standards
has not affected the reported results of operations or financial position of
the company except for one of the new statements, No. 15 Intangible Assets
(RR15). This standard requires that product development expenses that fulfil
certain criteria, but not other research and development expenses, be stated
as assets and amortized over their estimated economic life. During 2002,
SEK 5.0 million was treated in this way. In accordance with RR15, prior
periods have not been restated as the statement is only to be applied
prospectively.
Quarterly Sales Variations
Biacore's total sales during the period 2000-2002 were split between quarters
as follows:
Quarter 1 23% Quarter 3 22%
Quarter 2 23% Quarter 4 32%
Dividend
Reflecting Biacore's continued strong cash flow, the Board will recommend to
the Annual General Meeting that the Company begins to pay dividends to its
shareholders. For the financial year 2002 the Board will recommend a dividend
payment of SEK 3.00 per share.
Outlook for the Full-Year 2003
Taking into consideration the general market conditions and currency
developments, Biacore's sales for the full-year 2003 are expected to increase
by approximately 10%. Earnings per share are forecast to increase by
approximately 70% in 2003. Earnings per share will be positively affected by a
considerable reduction of the tax rate compared with full-year 2002 and the
capitalization of R&D expenses of approximately SEK 40 million in accordance
with Swedish accounting rules. As always, sales and earnings are expected to
vary substantially between the quarters.
The Annual General Meeting will be held on Thursday, May 8, 2003 at 4.30 p.m.
in Uppsala.
Uppsala, Sweden, February 21, 2003
Biacore International AB (publ)
The Board of Directors
Financial Information
Biacore's Annual Report will be distributed to the shareholders in mid April.
The Annual Report will also be available from that time on Biacore's website.
During 2003, Biacore plans to release its interim reports as follows:
January - March Thursday, May 8
January - June Friday, July 18
January - September Wednesday, October 22
Nominating Committee
The Annual General Meeting has decided to establish a nominating committee
with the task to propose to the Annual General Meeting:
1. the number of Board members to be elected,
2. the election of Board members,
3. remuneration to the members of the Board.
The nominating committee consists of the following people:
Lars-Goran Andren, Chairman of the Board; Inger Brattne, Pharmacia;
Marianne Nilsson, Robur; and Peter Rudman, Nordea.
Biacore is a global market leader in Surface Plasmon Resonance (SPR)
technology based systems with its own sales operations in the U.S., across
Europe, Japan, Australia and New Zealand. A strong patent portfolio protects
Biacore's SPR technology. Target groups for the Company's products consist
primarily of medical and life science research laboratories and pharmaceutical
and biotechnology companies around the world. Biacore is focusing on drug
discovery and development as its prime areas for future growth. Based in
Uppsala, Sweden, the Company is listed on the Stockholm Stock Exchange and
Nasdaq in the U.S.
This press release contains certain forward-looking statements within the
meaning of the United States Private Securities Litigation Reform Act of 1995
which, by their nature, involve risk and uncertainty because they relate to
events and depend on circumstances that will occur in the future. There are a
number of factors that could cause actual results and developments to differ
materially from those expressed or implied by these forward-looking statements.
More information on Biacore is available at the Company's website:
www.biacore.com
Biacore Consolidated Income Statements
January-December October-December
SEK million 2002 2001 Change 2002 2001 Change
Sales 614.2 543.7 13% 175.9 175.0 1%
Cost of goods sold -100.9 -99.8 1% -28.5 -32.1 -11%
Marketing -199.8 -188.7 6% -53.4 -56.3 -5%
Administration -68.3 -86.7 -21% -13.6 -28.3 -52%
Research and development -104.4 -104.7 0% -26.3 -27.0 -3%
Other income and expenses 4.3 5.3 -4.5 -4.3
Amortization of goodwill -4.5 -5.0 -1.1 -1.3
Operating income 140.6 64.1 119% 48.5 25.7 89%
Financial items, net -20.4 13.8 1.1 2.0
Income after financial items 120.2 77.9 54% 49.6 27.7 79%
Income taxes -40.1 -27.6 -9.1 -11.0
Minority interest 0.7 - 0.1 -
Net income 80.8 50.3 40.6 16.7
Basic earnings per share, SEK 8.28 5.16 4.16 1.71
Diluted earnings per share, SEK 8.20 5.04 4.15 1.68
No. of shares, average, diluted,
thousands 9,851 9,981 9,786 9,957
Net income 80.8 50.3 40.6 16.7
Stock options issued - 18.2 - 5.4
Currency translation differences -15.3 6.6 -2.7 -6.2
Change in shareholders' equity 65.5 75.1 37.9 15.9
Quarterly Income Statements
4Q 3Q 2Q 1Q 4Q 3Q 2Q 1Q
SEK million 2002 2002 2002 2002 2001 2001 2001 2001
Sales 175.9 142.4 154.6 141.3 175.0 113.8 122.4 132.5
Cost of goods sold -28.5 -22.9 -25.1 -24.4 -32.1 -20.3 -23.8 -23.6
Marketing -53.4 -47.9 -55.6 -42.9 -56.3 -45.6 -47.8 -39.0
Administration -13.6 -19.2 -19.5 -16.0 -28.3 -16.9 -18.5 -23.0
Research and development -26.3 -23.5 -32.3 -22.3 -27.0 -22.8 -29.7 -25.2
Other income and expenses -4.5 2.5 11.2 -4.9 -4.3 2.2 2.1 5.3
Amortization of goodwill -1.1 -1.1 -1.1 -1.2 -1.3 -1.2 -1.3 -1.2
Operating income 48.5 30.3 32.2 29.6 25.7 9.2 3.4 25.8
Financial items, net 1.1 -10.4 -12.7 1.6 2.0 7.0 2.6 2.2
Income after financial
items 49.6 19.9 19.5 31.2 27.7 16.2 6.0 28.0
Income taxes -9.1 -8.7 -12.2 -10.1 -11.0 -5.6 -2.0 -9.0
Minority interest 0.1 0.1 0.1 0.4 - - - -
Net income 40.6 11.3 7.4 21.5 16.7 10.6 4.0 19.0
Basic earnings per
share, SEK 4.16 1.16 0.75 2.21 1.71 1.09 0.41 1.95
Diluted earnings per
share, SEK 4.15 1.16 0.75 2.17 1.68 1.07 0.40 1.91
No. of shares, average,
diluted, thousands 9,786 9,750 9,896 9,918 9,957 9,930 10,023 9,943
Sales by region
Full year 4Q 3Q 2Q 1Q 4Q 3Q 2Q 1Q
SEK million 2002 2001 2002 2002 2002 2002 2001 2001 2001 2001
Americas 270.5 249.3 63.8 59.6 80.8 66.3 63.4 57.1 54.7 74.1
Europe 173.9 151.0 62.7 44.2 36.5 30.5 63.5 24.9 39.8 22.8
Asia-Pacific 169.8 143.4 49.4 38.6 37.3 44.5 48.1 31.8 27.9 35.6
Total sales 614.2 543.7 175.9 142.4 154.6 141.3 175.0 113.8 122.4 132.5
Biacore Consolidated Balance Sheets
December 31
SEK million 2002 2001
Intangible assets 84.8 84.3
Property, plant and equipment 117.1 107.6
Long-term investments 7.9 40.5
Other long-term assets 27.7 28.7
Other current assets 242.3 249.0
Liquid funds 351.6 220.8
Total assets 831.4 730.9
Shareholders' equity 634.7 569.2
Minority interest 0.9 -
Provisions 83.4 64.2
Liabilities 112.4 97.5
Total shareholders' equity
and liabilities 831.4 730.9
Financial structure
Operating capital 327.4 336.5
Long-term investments 7.9 40.5
Net interest-bearing assets 313.9 193.1
Net payable and deferred
income tax liability -13.6 -0.9
Minority interest -0.9 -
Shareholders' equity 634.7 569.2
Biacore Consolidated Statements of Cash Flows
January-December
SEK million 2002 2001
Net income 80.8 50.3
Less: Depreciation and amortization 23.7 20.5
Less: Write-down of long-term investments 28.7 -
Change in working capital 37.1 -53.9
Other -6.6 1.4
Cash flows from operating activities 163.7 18.3
Acquisition of business, net of cash acquired 1.6 -
Purchase of intangible assets -7.0 -57.5
Purchase of property, plant and equipment -31.7 -40.0
Proceeds from sale of long-term investments - 32.2
Cash flows from investing activities -37.1 -65.3
Change in financial liabilities 4.2 -
Cash flows from financing activities 4.2 -
Net change in liquid funds 130.8 -47.0
Key figures
Operating margin 22.9% 11.8%
Return on operating capital 42.4% 24.4%
Return on equity 13.4% 9.5%
Equity ratio 76% 78%
Shareholders' equity per share, diluted, SEK 64.44 56.96
No. of shares, thousands 9,750 9,750
No. of shares, end of period, diluted, thousands 9,849 9,993
No. of shares, average, diluted, thousands 9,851 9,981
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Biacore International AB (publ)
By: Lars-Olov Forslund
Name: Lars-Olov Forslund
Title: Chief Financial Officer
Dated: March 17, 2003